Question

A young male presents with rapidly worsening kidney function. Urinalysis shows hematuria, 3+ proteinuria, and red blood cell casts. His serum creatinine is 3.2 mg/dL. Chest imaging reveals bilateral pulmonary nodules. Which of the following is the most appropriate initial management?

• A. Methylprednisolone pulse followed by oral prednisolone and cyclophosphamide
• B. Only avacopan for induction
• C. Rituximab+oral gluucocorticoids
• D. Prednisolone+methotrexate (await biopsy)

Hint:

In any patient presenting with Pulmonary-Renal Syndrome (hemoptysis/pulmonary nodules + RPGN), empirical induction therapy must be initiated immediately while awaiting serology (ANCA, anti-GBM) or biopsy results. Delaying treatment in RPGN leads to permanent nephron loss.

Answer 1

The Correct Option is A

Concept:
The clinical scenario of rapidly progressive glomerulonephritis (RPGN) characterized by acute kidney injury (creatinine 3.2 mg/dL), active urinary sediment (RBC casts, hematuria, proteinuria), and concurrent pulmonary involvement (nodules) strongly suggests a Pulmonary-Renal Syndrome.
Given the nodular pulmonary presentation alongside RPGN, Granulomatosis with Polyangiitis (GPA, formerly Wegener's) or Microscopic Polyangiitis (MPA)—both ANCA-associated vasculitides (AAV)—are the top differential diagnoses.
Explanation:

• ANCA-associated vasculitis with severe, organ-threatening manifestations (such as rapidly progressive renal failure or pulmonary hemorrhage) requires aggressive and immediate remission-induction therapy.

• The standard of care for inducing remission in severe, life-threatening AAV is high-dose pulse intravenous Methylprednisolone followed by high-dose oral steroids, combined with either Cyclophosphamide (CYC) or Rituximab.

• Option (A) describes the classic, time-tested induction regimen for severe AAV: Pulse steroids to immediately halt the acute inflammatory cascade, followed by Cyclophosphamide.

• Option (B) is incorrect. Avacopan is a C5a receptor antagonist used as an adjunct to reduce steroid burden in AAV, but it is not used as a sole monotherapy for severe induction.

• Option (C) mentions Rituximab plus oral glucocorticoids. While Rituximab is non-inferior to CYC for induction, in cases with rapidly worsening severe renal failure (creatinine $>$ 3.0 mg/dL), Cyclophosphamide has historically been the agent of choice, though Rituximab is now commonly used. However, the lack of pulse IV steroids in Option C makes Option A the more robust and appropriate choice for a rapidly crashing patient.

• Option (D) is incorrect. Methotrexate is reserved for non-severe, non-organ-threatening AAV (e.g., isolated sinus disease without renal failure) and is contraindicated in severe renal failure. Delaying definitive therapy to await a biopsy in rapidly progressive pulmonary-renal syndrome can lead to irreversible organ loss or death.
Final answer:
High-dose pulse steroids followed by a combination of oral steroids and cyclophosphamide is the most definitive and proven initial management for severe organ-threatening AAV.